Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Prognostic Performance of ARC-HBR Criteria in Cancer Patients With Severe Coronary Disease
Session:
Sessão de Posters 03 - Cardio-oncologia e doença sistémica: onde o cancro encontra o coração
Speaker:
Daniel Inácio Cazeiro
Congress:
CPC 2026
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.6 Cardio-Oncology
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Daniel Inácio Cazeiro; Diogo Ferreira; Tiago Rodrigues; Ana Rita Francisco; João Silva Marques; Cláudia Jorge; Pedro Carrilho Ferreira; José Almeida Duarte; José Marques da Costa; Pedro Cardoso; Miguel Nobre Menezes; Fausto J. Pinto
Abstract
<p><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Introduction:</strong></span></span></span><br /> <span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">Cancer patients frequently present with complex coronary disease and elevated ischemic and bleeding risks. The ARC-HBR criteria were developed to identify patients at high bleeding risk, but their performance in cardio-oncology populations remains insufficiently characterized. This study evaluated the ability of ARC-HBR to predict major bleeding in cancer patients with severe coronary disease treated across different revascularization strategies.</span></span></span></p> <p> </p> <p><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Methods:</strong></span></span></span><br /> <span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">We conducted a retrospective study of 150 consecutive cancer patients from 2017 to 2023 with severe coronary disease who underwent PCI, CABG, or, when revascularization was not feasible, were treated with DAPT or single antiplatelet therapy plus anticoagulation for at least 6 months. ARC-HBR status was determined according to the original definition. Baseline characteristics, angiographic data, and clinical outcomes were compared between ARC-HBR and non–ARC-HBR patients. Major bleeding was defined as BARC type 3 or 5. Logistic regression assessed associations with major bleeding and mortality. Mean follow-up was 3.4 years.</span></span></span></p> <p> </p> <p><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Results:</strong></span></span></span><br /> <span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">Ninety-nine patients (66%) met ARC-HBR criteria and 51 (34%) were classified as non–ARC-HBR. Baseline cardiovascular risk factors and angiographic characteristics were generally comparable between groups. Age tended to be higher in ARC-HBR patients, and chronic kidney disease was markedly more prevalent (62% vs 26%, p<0.001). Hemoglobin and platelet levels were lower in ARC-HBR patients, though without statistical significance. As expected, active malignancy occurred exclusively in the ARC-HBR group, as it constitutes a major criterion.</span></span></span></p> <p> </p> <p><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">Major bleeding occurred in 15 patients (10%), with substantially higher rates in ARC-HBR compared with non–ARC-HBR patients (14% vs 2%, p=0.018). In ARC-HBR patients, the 3.4-year mean follow-up corresponds to an annualized major bleeding rate of 4.1 events per 100 patient-years, closely matching the ≥4% 1-year risk threshold that defines ARC-HBR. ARC-HBR status was associated with an eight-fold increase in major bleeding risk (OR 8.24, p=0.045) and a significant rise in mortality (OR 5.08, p<0.001).</span></span></span></p> <p> </p> <p><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"><strong>Conclusion:</strong></span></span></span><br /> <span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000">In cancer patients with severe coronary disease, ARC-HBR status effectively identified individuals at substantially higher risk of major bleeding and mortality, supporting its applicability and internal validity in this cardio-oncology population.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site